Viatris agrees to pay $264M to settle EpiPen class action case
Just as Biocon signs off on a $3.3 billion buyout of their shared biosimilars business, Viatris’s pending lawsuit for its controversial EpiPen might be no more — if the court signs off on it.
Keeping details short, the pharma snuck in an announcement about its EpiPen product in its Q4 report:
The Company has agreed, subject to approval by the Court, to a $264 million settlement, while denying any allegation of wrongdoing, to resolve the EpiPen Auto-Injector indirect purchaser class action cases pending in the U.S. District Court for the District of Kansas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.